BrightSpring Health Services BTSG
United StatesHealthcare · Health Information ServicesUSD
78.94 USD (+23.7%)
17 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
BrightSpring Health Services is a US provider of home healthcare, specialty pharmacy, and support services for people with intellectual and developmental disabilities, operating through an integrated community-based care network.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Strong growth9.2
- ✕Little or no dividend1.5
- ✕Unfavourable risk and backdrop2.5
- ✕Demanding valuation4.5
AI analysis
bottom line, main risk, context and newsStrong growth and cash generation justify the premium, but the low operating margin and demanding valuation limit near-term upside.
BrightSpring shows exceptional growth (revenue +23%, earnings +196%) with 164% cash conversion, although its current valuation (P/E 56.46) already discounts much of that potential; financial health is acceptable (ND/EBITDA 2.93) and the 3.37% operating margin is the weak point.
The 3.37% operating margin is very thin for a healthcare services business with debt (ND/EBITDA 2.93), making it vulnerable to labor cost pressures or regulatory changes in the US healthcare sector.
Context and risks
No recent news and no material exposure to current macro factors (rates, oil, tariffs) not already covered by quantitative metrics. The home healthcare and specialty pharmacy business does not depend on commodities or shipping routes, and its debt (ND/EBITDA 2.93) is at a manageable level that does not make the rate hike an aggravating risk.
Is BrightSpring Health Services stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 88% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 56.5 | 26.7 | +111% |
| EV / EBITDA | 23.9 | 14.5 | +65% |
| Price / book | 6.4 | 4.1 | +56% |
| Price / sales | 0.9 | 3.4 | −74% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 4.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 78.94 USD, +23.7% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 5.3 (sector 5.5), Growth 9.2 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 56.5
- Forward P/E
- 28.0
- EV / EBITDA
- 23.9
- Price / book
- 6.4
- Price / sales
- 0.9
- PEG
- 0.80
- Market cap
- 12.6B USD
- Enterprise value
- 15.0B USD
Profitability
- ROE
- 13.0%
- ROA
- 4.9%
- ROIC (approx.)
- 11.1%
- Gross margin
- 12.4%
- Operating margin
- 3.4%
- Net margin
- 2.5%
- Free cash flow
- 1.0B USD
- FCF yield
- 8.1%
- Cash conversion
- 164%
Solvency
- Total debt
- 2.4B USD
- Net debt
- 1.8B USD
- Cash
- 550.4M USD
- EBITDA
- 626.8M USD
- Net debt / EBITDA
- 2.93
- Debt / equity
- 116.01
- Current ratio
- 1.59
- Quick ratio
- 1.20
Growth
- Revenue growth
- +23.0%
- Earnings growth
- +196.6%
- EPS (TTM)
- 1.13 USD
- EPS (forward)
- 2.28 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.88
- Analyst consensus
- Strong buy (17)
- Target price
- 78.94 USD
- 52-week range
- 27.11 – 73.75
Recent news
All BTSG news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about BrightSpring Health Services
Is BrightSpring Health Services stock cheap or expensive?
On P/E and EV / EBITDA, it trades 88% above the Healthcare median on average. Valuation score: 4.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 78.94 USD, +23.7% versus the price. This is not investment advice.
What score does BrightSpring Health Services get on MeridIAn Screener?
It scores 5.2 out of 10, rank 1,573 of 2,130 (better than 24% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is BrightSpring Health Services's P/E ratio?
Its P/E is 56.5: the share price equals 56.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 28.0.
How much is BrightSpring Health Services worth on the stock market?
Its market capitalisation is 12.6B USD and its enterprise value, debt included, is 15.0B USD.
How much debt does BrightSpring Health Services have?
Its net debt (debt minus cash) is 1.8B USD. That is 2.93 times its EBITDA; the Healthcare median is 1.53.
Does BrightSpring Health Services pay a dividend?
It pays no dividend, or almost none.
How has BrightSpring Health Services stock performed over the last year?
It has risen 125.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 27.11 and 73.75 USD. Past performance does not guarantee future results.
What do analysts think of BrightSpring Health Services?
17 analysts cover it; their average recommendation is “Strong buy” and their average target is 78.94 USD (+23.7% versus the price). It is an estimate, not market data.